Nuclear β-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Uchino, Masahiro ^a   Kojima, Hiroko ^a,c   Wada, Kenta ^a,d   Imada, Mika ^b,e   Onoda, Fumitoshi ^b   Satofuka, Hiroyuki ^a   Utsugi, Takahiko ^a   Murakami, Yasufumi ^a,b  

^a Bio Matrix Research Inc   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c ATTO Corporation   (Japan)

^d TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

^e Pharmaceutical BTO Unit   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD24 ANTIGEN; HERMES ANTIGEN; OSTEOGENIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; UVOMORULIN; VIMENTIN; CTNNB1 PROTEIN, HUMAN; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CARCINOGENESIS; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA ISOLATION; UPREGULATION; XENOGRAFT; BREAST TUMOR; CANCER INVASION; CELL ADHESION; CELL MOTION; CELL NUCLEUS; DNA MICROARRAY; DRUG SCREENING; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENETICS; MESODERM; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING; WOUND HEALING;

ANTIGENS, CD24; ANTIGENS, CD44; BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; EPITHELIAL CELLS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GREEN FLUORESCENT PROTEINS; HUMANS; MESODERM; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955300455     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-414     Document Type: Article

References (57)

1. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006, 66:8319-8326. 10.1158/0008-5472.CAN-06-0410, 16951136.
2. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25:2273-2284. 10.1038/sj.onc.1209254, 16288205.
3. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:R25. 10.1186/bcr1982, 2397524, 18366788.
4. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumour. Science 1977, 197:893-895. 10.1126/science.887927, 887927.
5. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R, Wu CW. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997, 17:353-360.
6. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007, 67:1979-1987. 10.1158/0008-5472.CAN-06-1479, 17332325.
7. Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Research 2007, 17:3-14. 10.1038/sj.cr.7310118, 17179981.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
9. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Badve S, Nakshatri H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8:R59. 10.1186/bcr1610, 1779499, 17062128.
10. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-messenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
11. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000, 148:779-790. 10.1083/jcb.148.4.779, 2169367, 10684258.
12. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 2007, 117:206-217. 10.1172/JCI29293, 1679965, 17160136.
13. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981. 10.1083/jcb.200601018, 2063755, 16567498.
14. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992, 150:534-544. 10.1002/jcp.1041500314, 1537883.
15. Pinkas J, Leder P. MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. Cancer Res 2002, 62:4781-4790.
16. Lou Y, Preobrazhenska O, auf dem Keller U, Sutcliffe M, Barclay L, McDonald PC, Roskelley C, Overall CM, Dedhar S. Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Dev Dyn 2008, 237:2755-2768. 10.1002/dvdy.21658, 18773493.
17. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005, 65:5996-6000. 10.1158/0008-5472.CAN-05-0699, 16024596.
18. Planas-Silva MD, Waltz PK. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2007, 104:11-21. 10.1016/j.jsbmb.2006.09.039, 17197171.
19. Lim SC, Lee MS. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 2002, 9:915-928.
20. van Es JH, Barker N, Clevers H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 2003, 13:28-33. 10.1016/S0959-437X(02)00012-6, 12573432.
21. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Migrating cancer stem cells - an integrated concept of malignant tumor progression. Nat Rev Cancer 2005, 5:744-749. 10.1038/nrc1694, 16148886.
22. Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 2006, 127:139-155. 10.1016/j.cell.2006.08.036, 17018282.
23. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28:151-166. 10.1007/s10555-008-9179-y, 19153669.
24. Ackland ML, Newgreen DF, Fridman M, Waltham MC, Arvanitis A, Minichiello J, Price JT, Thompson EW. Epidermal growth factor-induced epithelio-mesenchymal transition in human breast carcinoma cells. Lab Invest 2003, 83:435-448.
25. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006, 66:11271-11278. 10.1158/0008-5472.CAN-06-2044, 17145872.
26. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009, 174:1588-1593. 10.2353/ajpath.2009.080545, 2671246, 19342369.
27. Silver DL, Geisbrecht ER, Montell DJ. Requirement for JAK/STAT signaling throughout border cell migration in Drosophila. Development 2005, 132:3483-3492. 10.1242/dev.01910, 16000386.
28. Chédotal A. Chemotropic axon guidance molecules in tumorigenesis. Prog Exp Tumor Res 2007, 39:78-90. full_text, 17314502.
29. Ritch PA, Carroll SL, Sontheimer H. Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. J Biol Chem 2003, 278:20971-20978. 10.1074/jbc.M213074200, 12600989.
30. Servant G, Weiner OD, Herzmark P, Balla T, Sedat JW, Bourne HR. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science 2000, 287:1037-1040. 10.1126/science.287.5455.1037, 2822871, 10669415.
31. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP. New insights into the biology of the acute phase response. J Clin Immunol 1999, 19:203-214. 10.1023/A:1020563913045, 10471974.
32. Lauffenburger DA, Horwitz A. Cell migration: a physiologically integrated molecular process. Cell 1996, 84:359-369. 10.1016/S0092-8674(00)81280-5, 8608589.
33. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA. The phosphatidylinositol 3'-kinase p85α genes is an oncogene in human ovarian and colon tumors. Cancer Res 2001, 61:7426-7429.
34. Piessevaux J, Lavens D, Montoye T, Wauman J, Catteeuw D, Vandekerckhove J, Belsham D, Peelman F, Tavernier J. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem 2006, 281:32953-32966. 10.1074/jbc.M600776200, 16956890.
35. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massagué J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115:44-55. 539194, 15630443.
36. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 2003, 100:8621-8623. 10.1073/pnas.1633291100, 166359, 12861075.
37. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990, 87:7678-7682. 10.1073/pnas.87.19.7678, 54811, 2217201.
38. Fournier PG, Guise TA. BMP7: a new bone metastases prevention?. Am J Pathol 2007, 171:739-743. 10.2353/ajpath.2007.070582, 1959486, 17690188.
39. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007, 67:8742-8751. 10.1158/0008-5472.CAN-06-2490, 17875715.
40. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-15670. 10.1073/pnas.95.26.15665, 28101, 9861027.
41. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E, Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007, 104:16158-16163. 10.1073/pnas.0702596104, 2042178, 17911267.
42. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007, 3:7-17. 10.1007/s12015-007-0004-8, 17873377.
43. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-5511. 10.1158/0008-5472.CAN-05-0626, 15994920.
44. De Larco JE, Wuertz BRK, Manivel JC, Furcht LT. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001, 61:2857-2861.
45. Yin L, Castagnino P, Assoian RK. ABCG2 expression and side population abundance regulated by a transforming growth factor β-directed epithelial-mesenchymal transition. Cancer Res 2008, 68:800-807. 10.1158/0008-5472.CAN-07-2545, 18245481.
46. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007, 356:217-226. 10.1056/NEJMoa063994, 17229949.
47. Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJ. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene 2006, 25:6079-6091. 10.1038/sj.onc.1209628, 16652145.
48. Schabath H, Runz S, Joumaa S, Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006, 119:314-325. 10.1242/jcs.02741, 16390867.
49. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
50. Katoh S, Matsumoto N, Kawakita K, Tominaga A, Kincade PW, Matsukura S. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest 2003, 111:1563-1570. 155042, 12750406.
51. Hamada J, Sawamura Y, Van Meir EG. CD44 expression and growth factors. Front Biosci 1998, 3:d657-d664.
52. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999, 154:515-523. 1850011, 10027409.
53. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008, 68:3655-3661. 10.1158/0008-5472.CAN-07-2940, 18483247.
54. Suzuki H, Masuda N, Shimura T, Araki K, Kobayashi T, Tsutsumi S, Asao T, Kuwano H. Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res 2008, 28:1821-1830.
55. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal- like breast cancers and predicts poor outcome. Am J Pathol 2010, 176:2911-2920. 10.2353/ajpath.2010.091125, 20395444.
56. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
57. Loi S. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?. Eur J Cancer 2008, 44:2813-2818. 10.1016/j.ejca.2008.09.012, 18990560.